Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia ‐Pacific region: Post‐hoc analyses of pooled clinical study data

ConclusionIn Asia ‐Pacific patients, tofacitinib improved signs/symptoms over 24 months. Safety over 92 months was generally consistent with global tofacitinib studies; however, infection IRs were higher in Asia‐Pacific patients.

Source: International Journal of Rheumatic Diseases - March 21, 2019 Category: Rheumatology Authors: Eun Bong Lee, Hisashi Yamanaka, Yi Liu, Wen ‐Chan Tsai, Connie Chen, Kenneth Kwok, Hyun–Jeong Yoo, Lyndon J. Llamado, Lisy Wang, Yingchun Luo, Naonobu Sugiyama, Yoshiya Tanaka Tags: ORIGINAL ARTICLE Source Type: research